Spreedly collaborates with EBANX to support payments in LatAm
Open payments platform Spreedly has partnered with payments provider EBANX to facilitate access to alternative payment methods for international companies in Latin America.
The collaboration offers a framework for businesses to incorporate payment methods that include Pix, e-wallets, cash vouchers, and local debit and credit cards, with the option of instalments.
The initiative covers all 17 countries where EBANX operates, encompassing markets such as Brazil, Mexico, and Colombia, as well as Peru and Chile, and extending to Central America and the Caribbean.
The launch of Pix Automático is scheduled for June 2025, facilitating recurring payments for streaming services and SaaS providers.
Merchants can access integration processes, access to various local markets, and an array of payment options to scale operations and compliance with local regulations.
The partnership will help merchants capitalise on the 'high transaction success rates' of both Spreedly and EBANX, the release added.
Spreedly partnerships & business development VP Rose François said: 'Latin America is a key market for global expansion, with diverse payment preferences driving success. Our collaboration with EBANX empowers merchants to offer local payment methods, enhancing customer satisfaction while supporting business growth in the region.'
'This partnership combines Spreedly's advanced payments orchestration with EBANX's local expertise, providing a seamless payment experience for customers and helping businesses scale efficiently across Latin America.'
EBANX global partnerships VP head Daniel Kornitzer stated: "Over the past year, Pix transactions processed by EBANX have grown by 139%. Merchants using our technology already see a 25% increase in the number of customers and a 16% rise in revenue. Offering Pix is no longer optional; it's essential."
Kornitzer added: 'Spreedly's efficient orchestration and intelligent routing, and EBANX's optimised payment rails, direct integrations, and local acquiring partnerships, enable faster, more secure transactions. This helps improve customer satisfaction and loyalty.'
In February, Spreedly partnered with Swedish fintech Trustly to provide merchants with access to Pay by Bank, aiming to improve payment efficiency in both regional and international markets.
"Spreedly collaborates with EBANX to support payments in LatAm " was originally created and published by Electronic Payments International, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
Zara owner Inditex flags slowing summer sales as quarterly revenues miss expectations
Zara owner Inditex on Wednesday posted weaker-than-expected quarterly sales while flagging a slower start to the summer season than last year amid broader economic uncertainty. The Spanish retailer reported revenues of 8.27 billion euros ($9.44 billion) in the fiscal first quarter covering Feb. 1 to April 30, slightly shy of the 8.39 billion euros forecast by LSEG analysts. Net income came in at 1.3 billion euros for the quarter, compared to the 1.32 billion euros analysts estimated. The company also reported a slower start to summer sales, which increased 6% at constant currencies from May 1 to June 9 versus 12% growth in the same period last year on a constant currency basis. Back in March, Inditex flagged a slowdown in demand at the start of the year, which CEO Óscar García Maceiras at the time attributed to uncertainty around U.S. tariffs. Shares plunged on the comments and the stock currently remains down around 12% from its Dec. 4 peak, as of Monday. The comments came as Inditex sales rose annually in the fourth quarter to 11.21 billion, meeting expectations. It followed a rare miss on sales and profit in the third quarter as flooding in Spain impacted consumer spending. The company, which also owns a series of high street brands including Pull & Bear, Bershka and Massimo Dutti, is often seen as a barometer for broader consumer sentiment. It has also been etching out a clear lead on high street rival H&M, which posted weaker-than-expected fiscal first quarter revenues in March, as sales continue to soften at the Swedish fashion giant. The two retail giants have nevertheless struggled with increased competition from lower-cost fast fashion brands such as Chinese-founded Shein and Temu.
Yahoo
4 hours ago
- Yahoo
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech ABSalipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong PharmaceuticalDaewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd.
Business Upturn
13 hours ago
- Business Upturn
Photowall Brings Scandinavian Wall Design to Japan
STOCKHOLM, June 10, 2025 (GLOBE NEWSWIRE) — Photowall , the Swedish interior design company renowned for its custom wall murals, wallpapers, and canvas prints, is proud to announce its official entry into the Japanese market. From now on, Japanese customers can explore and shop the full Photowall collection in their local language at , marking a major milestone in the company's ongoing global expansion. With a strong presence across Europe and North America, Photowall's move into Japan reflects the brand's commitment to making personalized interior design accessible to a wider international audience. The launch includes a comprehensive marketing campaign, local customer support, and tailored logistics to ensure a seamless experience for customers in Japan. 'We're thrilled to bring our products and design philosophy to Japan, a country that shares our appreciation for craftsmanship, aesthetics, and individuality,' a company spokesperson said. 'Japan's design culture is both rich and globally influential, making it a natural next step for us. We're excited to see how our wall art collections will inspire new creative spaces across the country.' Founded in 2006 in Sweden, Photowall offers a vast library of wall decor — from striking nature scenes and minimalist patterns to exclusive artwork by international designers. Customers can also upload their own images to create one-of-a-kind wallpaper or prints, making every product deeply personal. All items are made to order in Stockholm using eco-friendly materials and water-based inks, ensuring minimal environmental impact. Japanese customers will benefit from a fully localized shopping experience, which features local currency, language, customer service, and optimized shipping. The site will also feature local design inspiration and partnerships with Japanese influencers, artists, and interior design experts. Photowall's products are particularly well-suited to Japan's evolving interior design trends, which increasingly embrace customization, biophilic design, and sustainable materials. Whether decorating a small apartment in Tokyo or a traditional home in Kyoto, Japanese homeowners and businesses can now transform their walls with designs that reflect their personality and values. The Japanese launch builds on Photowall's strong global momentum, as the company now serves customers in over 25 international markets. With a growing reputation for quality, fast production, and highly customizable design options, Photowall continues to gain loyal customers around the world — particularly in the United States, where its dedicated storefront at has seen strong demand across both residential and commercial segments. For more information, visit: A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
